参考文献

2020-10-21

1: Villetti G, Carnini C, Battipaglia L, Preynat L, Bolzoni PT, Bassani F, Caruso P, Bergamaschi M, Pisano AR, Puviani V, Stellari FF, Cenacchi V, Volta R, Bertacche V, Mileo V, Bagnacani V, Moretti E, Puccini P, Catinella S, Facchinetti F, Sala A, Civelli M. CHF6001 II: a novel phosphodiesterase 4 inhibitor, suitable for topical pulmonary administration--in vivo preclinical pharmacology profile defines a potent anti-inflammatory compound with a wide therapeutic window. J Pharmacol Exp Ther. 2015 Mar;352(3):568-78. doi: 10.1124/jpet.114.220558. Epub 2015 Jan 9. PubMed PMID: 25576073.

2: Ochiana SO, Bland ND, Settimo L, Campbell RK, Pollastri MP. Repurposing human PDE4 inhibitors for neglected tropical diseases. Evaluation of analogs of the human PDE4 inhibitor GSK-256066 as inhibitors of PDEB1 of Trypanosoma brucei. Chem Biol Drug Des. 2015 May;85(5):549-64. doi: 10.1111/cbdd.12443. Epub 2014 Nov 18. PubMed PMID: 25283372; PubMed Central PMCID: PMC4385514.

3: Song SD, Tang HF. [Progress in PDE4 targeted therapy for inflammatory diseases]. Zhejiang Da Xue Xue Bao Yi Xue Ban. 2014 May;43(3):353-8. Review. Chinese. PubMed PMID: 24998661.

4: Watz H, Mistry SJ, Lazaar AL; IPC101939 investigators. Safety and tolerability of the inhaled phosphodiesterase 4 inhibitor GSK256066 in moderate COPD. Pulm Pharmacol Ther. 2013 Oct;26(5):588-95. doi: 10.1016/j.pupt.2013.05.004. Epub 2013 May 21. PubMed PMID: 23701917.

5: Nials AT, Tralau-Stewart CJ, Gascoigne MH, Ball DI, Ranshaw LE, Knowles RG. In vivo characterization of GSK256066, a high-affinity inhaled phosphodiesterase 4 inhibitor. J Pharmacol Exp Ther. 2011 Apr;337(1):137-44. doi: 10.1124/jpet.110.173641. Epub 2011 Jan 4. PubMed PMID: 21205924.

6: Tralau-Stewart CJ, Williamson RA, Nials AT, Gascoigne M, Dawson J, Hart GJ, Angell AD, Solanke YE, Lucas FS, Wiseman J, Ward P, Ranshaw LE, Knowles RG. GSK256066, an exceptionally high-affinity and selective inhibitor of phosphodiesterase 4 suitable for administration by inhalation: in vitro, kinetic, and in vivo characterization. J Pharmacol Exp Ther. 2011 Apr;337(1):145-54. doi: 10.1124/jpet.110.173690. Epub 2011 Jan 4. PubMed PMID: 21205923.

7: Tomillero A, Moral MA. Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2010 Sep;32(7):517-48. doi: 10.1358/mf.2010.32.7.1549223. PubMed PMID: 21069103.

8: Singh D, Petavy F, Macdonald AJ, Lazaar AL, O'Connor BJ. The inhaled phosphodiesterase 4 inhibitor GSK256066 reduces allergen challenge responses in asthma. Respir Res. 2010 Mar 1;11:26. doi: 10.1186/1465-9921-11-26. PubMed PMID: 20193079; PubMed Central PMCID: PMC2841147.